Icecure Medical

IceCure Medical is setting new standards in minimally invasive cryotherapy for women’s health and interventional oncology. Founded in 2006 to advance the treatment of cancerous tumors, our FDA-cleared and CE-marked ProSense™ Cryoablation System utilizes Liquid Nitrogen to generate ultra-cold temperatures quickly to create large lethal zones for maximum efficacy in tumor destruction. The ProSense™ system achieves a sharp temperature decrease at the start of the freeze step and provides consistently stable freezing temperatures throughout the procedure. ProSense™ is a proven solution for the treatment of benign and malignant breast tumors, renal, lung, liver, and bone cancers.

The ProSense™ system is a proven solution for the treatment of benign and malignant tumors, as well as renal, lung, liver, and bone cancer. The FDA cleared and CE marked ProSense™ system is available in the US, Europe, and across Asia in Singapore, Thailand, Japan, India, and Taiwan.

For women with breast tumors, the ProSense® System provides patients with safe and fast in-office cryoablation therapy with excellent cosmetic results. The ProSense® System is FDA-cleared for the treatment of fibroadenomas and in 2021 was granted FDA Breakthrough Device Designation for treatment of patients with T1 invasive breast cancer and/or patients not suitable for surgical alternatives for the treatment of breast cancer. IceCure is conducting the ICE3 Clinical Trial, the largest multi-center trial for cryoablation of small, low-risk breast cancer. Interim analysis of the ICE3 trial presented during ASBrS 2021 Annual Meeting show promising results - at a mean of 34.83 months following treatment with ProSense®, only 2.06% (4 out of 194 eligible trial patients) experienced cancer recurrence.

The ICE3 interim results were also published in the Annals of Surgical Oncology “Cryoablation Without Excision for Low-Risk, Early-Stage Breast Cancer: 3-Year Interim Analysis of Ipsilateral Breast Tumor Recurrence in the ICE3 Trial” with Dr. Richard Fine, MD, FACS, as the lead author.

*Clinical indications for use and regulatory cleareance for use vary by region.

IceCure Medical is committed to bringing innovative cryotherapy solutions to the field of women's health and interventional oncology. We aim to provide our customers with a high level of clinical support, stellar customer service, and a high quality and reliable product.